News | May 14, 2024
Sanofi India posts Q1 CY24 PAT at Rs. 136.6 Cr
Sanofi India has reported total income of Rs. 738.9 crores during the period ended March 31, 2024
Sanofi India has reported total income of Rs. 738.9 crores during the period ended March 31, 2024
‘Unmask Anemia’ aims to simplify assessment of iron deficiency anemia risk with an easy online self-test based on common signs and symptoms
George Svokos joins Avet after serving as a strategic business advisor to numerous global healthcare companies
It is a two dose vaccine to be administered intramuscularly at 28 days apart
_256_384.jpg)
The Indian companies that have been granted licences are Cipla, Sun Pharma, Laurus Labs, Divis Labs, Glenmark, Cadila, Torrent, Emcure, McLeods, SMS Pharmaceuticals, Strides, Biocon, Aurobindo Pharma, Hetero, Granules, Amneal, MSN, Arene Life Sciences and Viatris
Flattish volume growth and subdued new launches were key factors for last month
_256_384.jpg)
Ind-Ra expects IPM revenue growth of over 12% yoy for FY22.
The appraisal of the applications has been carried out based on the ranking methodology laid down in the operational guidelines of the Scheme
Contribution from the top five therapies stood at 58% of IPM in October 2021. These therapies are cardiac, anti-infectives, gastro-intestinal, anti-diabetic and vitamins
Ind-Ra continues to expect IPM’s revenue to grow over 12% yoy in FY22
Subscribe To Our Newsletter & Stay Updated
